-- 在Capital Power (CPX.TO)周三公布第一季度业绩后，加拿大帝国商业银行资本市场(CIBC Capital Markets)重申了对该公司股票的“跑赢大盘”评级，同时将目标股价从82加元下调至80加元。 CIBC认为，Capital Power业绩公布后股价的疲软并不合理，可能反映出投资者对该公司能否带来利好因素缺乏耐心。 CIBC表示：“然而，我们对CPX的中期增长前景依然充满信心。我们相信，随着阿尔伯塔省和PJM的政策更加明朗，现有资产（以及未来投资）的增值潜力将得以实现。” CIBC指出，数据中心和阿尔伯塔省二期工程的进展，以及美国经济增长的进展，都可能成为推动股价上涨的催化剂。 CIBC认为，股价疲软反而是一个买入良机。
Price: $65.62, Change: $+3.25, Percent Change: +5.20%
Toronto-Dominion Bank (TD.TO) after the close Thursday said it issued its seventh sustainable-labelled bonds for 150-million Swiss francs. The bank said its total sustainable bond issuances have now exceeded C$5.2 billion since 2014."TD's first European green bond continues building the strength of our sustainable financing program, helping us support clients pursuing sustainable investment in a new jurisdiction," said Nicole Vadori, head of sustainability at TD.TD shares closed up $3.40 at $146.33 on Toronto Stock Exchange.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Amgen delivered solid Q1 2026 results with revenues of $8.6B (+6% Y/Y), $50M above consensus, and non-GAAP EPS of $5.15 (+5% Y/Y), beating expectations by $0.38. The company demonstrated continued execution of its portfolio diversification strategy, with sixteen products achieving double-digit growth and seventeen products annualizing above $1B. We favorably view AMGN's broad-based growth across newer therapeutic franchises, with standout performances from Repatha (+34% Y/Y), TEPEZZA (+29% Y/Y), and TEZSPIRE (+20% Y/Y), offsetting expected declines in legacy products facing biosimilar competition. Management raised 2026 guidance to $37.1B-$38.5B in revenues and EPS of $21.70-$23.10. R&D expenses surged 16% Y/Y to $1.7B, reflecting intensive investments in the MariTide obesity program and multiple Phase 3 studies. We believe AMGN's successful portfolio transformation and strategic focus on high-growth therapeutic areas position it well for sustained long-term growth.